Investment area
Venture Investments
Region
North America
Date of investment
May 2020
Building on our knowledge of the medicinal chemistry, biological activity and mechanism of action of NLRP3 inflammasome inhibitors, NodThera are creating a next-generation pipeline of small molecules that are optimized for potency, PK and tissue penetration. NodThera are also optimizing for structural attributes that enable individual candidate molecules to be targeted to specific disease indications.
Contact
Naveed Siddiqi
Senior Partner
Department: Venture Investments
Naveed joined Novo Holdings A/S in 2019 and works from London and Copenhagen as a Senior Partner in Venture Investments.
He brings more than 25 years of experience in life science venture investments and investment banking. Between 2013 and 2018, he was Partner at Andera Partners, a Paris based venture capital and growth equity firm with over 2 billion euros under management, focusing on life science investing. He has also worked for Nomura Phase4 Ventures, Nomura International, EFG Corporate Finance, KPMG and as a medical doctor in the UK’s National Health Service. During his career he has served on multiple European and US boards including at Novo Holdings with the Boards of Amolyt SAS (acquired by AstraZeneca), Reviral (acquired by Pfizer), Vectivbio (IPO on NASDAQ and acquired by Ironwood), F2G, Alentis Therapeutics and Asceneuron. He has been a Board Observer on the board of Numab AG (sale of Yellow Jersey Therapeutics to J&J).
Naveed obtained his medical degree from Guy’s and St Thomas’s Hospital Medical School (now King’s College London). Later, he also qualified as a chartered accountant from the Institute of Chartered Accountants England & Wales.
